PURPOSE: Tumor-specific immunomonitoring is essential to evaluate the efficacy of vaccination against cancer. In this study, we investigated the predictive value of the presence or absence of antigen-specific T cells in biopsies from delayed-type hypersensitivity (DTH) sites. PATIENTS AND METHODS: In our ongoing clinical trials, HLA-A2.1+ melanoma patients were vaccinated with mature dendritic cells (DC) pulsed with melanoma-associated peptides (gp100 and tyrosinase) and keyhole limpet hemocyanin. RESULTS: After intradermal administration of a DTH challenge with gp100- and tyrosinase peptide-loaded DC, essentially all patients showed a positive induration. In clinically responding patients, T cells specific for the antigen preferentially accumulated in the DTH site, as visualized by in situ tetramer staining. Furthermore, significant numbers of functional gp100 and tyrosinase tetramer-positive T cells could be isolated from these DTH biopsies, in accordance with the applied antigen in the DTH challenge. We observed a direct correlation between the presence of DC vaccine-related T cells in the DTH biopsies of stage IV melanoma patients and a positive clinical outcome (P = .0012). CONCLUSION: These findings demonstrate the potency of this novel approach in the monitoring of vaccination studies in cancer patients.
PURPOSE:Tumor-specific immunomonitoring is essential to evaluate the efficacy of vaccination against cancer. In this study, we investigated the predictive value of the presence or absence of antigen-specific T cells in biopsies from delayed-type hypersensitivity (DTH) sites. PATIENTS AND METHODS: In our ongoing clinical trials, HLA-A2.1+ melanomapatients were vaccinated with mature dendritic cells (DC) pulsed with melanoma-associated peptides (gp100 and tyrosinase) and keyhole limpet hemocyanin. RESULTS: After intradermal administration of a DTH challenge with gp100- and tyrosinase peptide-loaded DC, essentially all patients showed a positive induration. In clinically responding patients, T cells specific for the antigen preferentially accumulated in the DTH site, as visualized by in situ tetramer staining. Furthermore, significant numbers of functional gp100 and tyrosinase tetramer-positive T cells could be isolated from these DTH biopsies, in accordance with the applied antigen in the DTH challenge. We observed a direct correlation between the presence of DC vaccine-related T cells in the DTH biopsies of stage IV melanomapatients and a positive clinical outcome (P = .0012). CONCLUSION: These findings demonstrate the potency of this novel approach in the monitoring of vaccination studies in cancerpatients.
Authors: Stefanie Gross; Michael Erdmann; Ina Haendle; Steve Voland; Thomas Berger; Erwin Schultz; Erwin Strasser; Peter Dankerl; Rolf Janka; Stefan Schliep; Lucie Heinzerling; Karl Sotlar; Pierre Coulie; Gerold Schuler; Beatrice Schuler-Thurner Journal: JCI Insight Date: 2017-04-20
Authors: An M T Van Nuffel; Daphné Benteyn; Sofie Wilgenhof; Lauranne Pierret; Jurgen Corthals; Carlo Heirman; Pierre van der Bruggen; Pierre G Coulie; Bart Neyns; Kris Thielemans; Aude Bonehill Journal: Mol Ther Date: 2012-02-28 Impact factor: 11.454
Authors: Steve Boudewijns; Martine Bloemendal; Winald R Gerritsen; I Jolanda M de Vries; Gerty Schreibelt Journal: Hum Vaccin Immunother Date: 2016-06-20 Impact factor: 3.452
Authors: Cécile Gouttefangeas; Cliburn Chan; Sebastian Attig; Tania T Køllgaard; Hans-Georg Rammensee; Stefan Stevanović; Dorothee Wernet; Per thor Straten; Marij J P Welters; Christian Ottensmeier; Sjoerd H van der Burg; Cedrik M Britten Journal: Cancer Immunol Immunother Date: 2015-02-18 Impact factor: 6.968
Authors: John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner Journal: Semin Immunol Date: 2008-06-09 Impact factor: 11.130
Authors: Cedrik Michael Britten; Sylvia Janetzki; Leah Ben-Porat; Timothy M Clay; Michael Kalos; Holden Maecker; Kunle Odunsi; Michael Pride; Lloyd Old; Axel Hoos; Pedro Romero Journal: Cancer Immunol Immunother Date: 2009-03-04 Impact factor: 6.968